04/21-04

PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995 are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/658,787 Filing Date September 9 2003 FORM First Named Inventor June et al. Art Unit (to be used for all correspondence after initial filing) 1632 **Examiner Name** To Be Assigned Attorney Docket Number 40 Total Number of Pages in This Submission 36119:140US2

| ENCLOSURES (Check all that apply) | | | | | | | | | | | |
|--|--|--|---|--|--|--|--|--|--|--|--|
| | Fee Transmittal Form | 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | ter Allowance communication Technology Center (TC) | | | | | | | | |
| | Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement (39 Pages) Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 | Petition Petition Petition Petition Power of Attorney, Revocation Change of Correspondence Address Correspondence Address Correspondence Address Correspondence Address Correspondence Address | opeal Communication to Board Appeals and Interferences opeal Communication to TC ppeal Notice, Brief, Reply Brief) oprietary Information atus Letter ther Enclosure(s) (please entify below): | | | | | | | | |
| | | | | | | | | | | | |
| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | | | | | | | | | |
| Firm or Individual name G011een Sup€ | | erko, Reg. No. 39,850 | | | | | | | | | |
| Signature Alllu | | Juxerko | | | | | | | | | |
| Date April 20, 20 | | / | | | | | | | | | |

EXPRESS MAIL LABEL NO. FV 22520177705 DATE OF DEPOSIT _____

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APR 2 0 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

June et al.

Art Unit:

1632

Serial No.:

10/658,787

Examiner:

To Be Assigned

Date Filed:

September 9, 2003

Conf. No.

1823

Docket No.:

36119.140US2

Cust. No.:

23483

Title:

Methods for Transfecting T Cells

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EV 22520177705

Express Mail No.

Date of Deposit

Sharon R. Matthews

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith the attached Forms PTO-1449 and Forms PTO-892 for filing in the above-referenced application. This application is a continuation of U.S. Application Serial No. 08/475,136, filed June 7, 1995 (now U.S. Patent No. 6,692,964). The attached Forms PTO-1449 and Forms PTO-892 stamped "copy" list references that were already submitted by the Applicants or cited by the Examiner in the parent application; therefore, pursuant to 37 C.F.R. § 1.98 (d), no copies of the previously cited art are enclosed; however, copies of the can be provided upon request.

The attached Form PTO-1449 listing the reference, "Culver et al." identifies the one new reference citation being made in the present application. The Culver et al. reference was

U.S. Appl. No. 10/658,787

Information Disclosure Statement

Page 2 of 2

brought to the Applicants' attention by Examiner Nguyen during the prosecution of parent

application, but was never formally cited in a Form PTO-892.

Copies of the corresponding PCT International Search Report, PCT Written Opinion and

PCT International Preliminary Examination Report (IPER) are also attached.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97 (b) (3), before

the mailing date of a first Office Action on the merits; therefore, no fee is believed to be due.

The submission of this statement is not a representation that a search has been made, or

that no better or other relevant art exists. This submission is also not an admission that any of

the cited references is, or is considered to be material to patentability or that any of the cited

references constitutes prior art to the invention. Moreover, the Applicants understand that the

Examiner will make an independent evaluation of the cited publications.

It is respectfully requested that the information above be expressly considered and that

the publications be made of record therein and appear among the "References Cited" on any

patent to issue therefrom. The Examiner is respectfully requested to initial the attached Forms

PTO-1449 and Forms PTO-892 and return them with the next Office Action.

Please charge any fees that might be due in connection with this matter to Deposit

Account No. 08-0219. If there are any questions, please call the undersigned at the telephone

number indicated below.

Respectfully submitted,

Date: April 20, 2004

Hale and Dorr LLP 60 State Street

Boston, MA 02109

Tel:

(617) 526-6564

Fax:

(617) 526-5000

-2-

| Subt. For, PTO-1449 | | | | | 1 | | | olication Number 0/658,787 | | | | |
|---------------------------|--|---------------------|---------------|------------------------|------------------------|--------------------|---------------------------------------|-------------------------------|-----------|--|--|--|
| // INFORMATION DISCLOSURE | | | | | | | | | | | | |
| | IN AN APPLICATION | | | | Applicant June et al. | | | | | | | |
| | (Us | se several sheets | s if necessa | ary) | | | | | | | | |
| | | | | Fili | | Group Art Unit | | | | | | |
| Sheet OF 1 | | | 1 | September 9, 2003 1632 | | | | | | | | |
| | 1 | APR 2 0 2004 (4) | | | | | | | | | | |
| U.S. Patent Documents | | | | | | | | | | | | |
| EXAMINER INITIAL | | ADOCUMENT NUMBER | DATE | DATE ! | | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | | | |
| | | | | | | | | | | | | |
| | | | | | | · | | | | | | |
| | ··· | | | | | <u> </u> | | | | | | |
| | | | | | | <u> </u> | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | F | oreign Pat | tent Docum | ents | | | | | | |
| EXAMINER INITIAL | | DOCUMENT | DATE | CC | DUNTRY | CLASS | SUBCLASS | TRANSLATION | | | | |
| | | NUMBER | | | ··· | | | YES | NO | | | |
| | | | | | | | | | | | | |
| | | | <u> </u> | | | | | | | | | |
| - | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | · | | | | | | | | | | |
| | | | Othe | er Docume | nts (Includin | g Author, Titl | e, Date Pertir | nent Page | es, Etc.) | | | |
| | Culver et al., "In Vivo Expression and Survival of Gene-Modified T Lymphocytes in Rhesus Monkeys," Human Gene Therapy, 1:399-410 (1990) | | | | | | | | | | | |
| | † · · · · | | (1000) | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | <u></u> | | | | | | | | | |
| | | | | . | | | | | | | | |
| | | | - · · · - | | | | | | | | | |
| | <u> </u> | | | | | | · · · · · · · · · · · · · · · · · · · | | | | | |
| EXAMII | NER | | | | DATE CONSIDERED | | | | | | | |
| | | | | | | | | | | | | |
| EXAM | EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | | | | | | | | | | | |
| citation | if not c | onformance and not | considered. I | include copy with | n next communic | cation to applicar | nt. | | | | | |